<DOC>
	<DOC>NCT00566111</DOC>
	<brief_summary>We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient, placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar disorder, currently depressed, who have failed to respond to conventional treatments.</brief_summary>
	<brief_title>Ceftriaxone in the Management of Bipolar Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Ceftriaxone</mesh_term>
	<criteria>DSMIV diagnosis of bipolar disorder Presence of a current major depressive episode on the SCID Score of 17 or greater on the HDRS Failure to respond to two previous medication trials Capable of giving voluntary written consent Hypersensitivity to penicillin or cephalosporin, resulting in anaphylaxis Significant current substance dependence/abuse within 3 months preceding the trial Significant history of intravenous drug abuse Active suicidal ideation Pregnant/lactating mothers Significant medical history Patients on anticoagulation treatment Patients who test positive for HIV or Hep B or C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Ceftriaxone</keyword>
	<keyword>Acute Antidepressant Effects</keyword>
	<keyword>Glutamatergic System</keyword>
	<keyword>Double-Blind</keyword>
	<keyword>Mood Disorders</keyword>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>Affective Disorders</keyword>
</DOC>